The clinical significance of SWI/SNF complex in pancreatic cancer

International Journal of Oncology

Volumn 42, Issue 2, 2013, Pages 403-410

  Numata, Masakatsu ^a   Morinaga, Soichiro ^a   Watanabe, Takuo ^b   Tamagawa, Hiroshi ^c   Yamamoto, Naoto ^a   Shiozawa, Manabu ^a   Nakamura, Yoshiyasu ^a   Kameda, Yoichi ^a   Okawa, Shinichi ^a   Rino, Yasushi ^c   Akaike, Makoto ^a   Masuda, Munetaka ^c   Miyagi, Yohei ^a  

^a KANAGAWA CANCER CENTER   (Japan)

^b YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Pancreatic cancer; Prognostic factor; The SWItch sucrose non fermentable complex

Indexed keywords

ADENOSINE TRIPHOSPHATE DERIVATIVE; BAF 180 PROTEIN; BAF 250A PROTEIN; BAF 47 PROTEIN; BARRIER TO AUTOINTEGRATION FACTOR; BIOLOGICAL MARKER; BRG1 PROTEIN; BRM PROTEIN; GEMCITABINE; SWI SNF PROTEIN COMPLEX; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHROMATIN ASSEMBLY AND DISASSEMBLY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME;

AGED; CELL NUCLEUS; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA HELICASES; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PANCREATIC NEOPLASMS; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84873645141     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1723     Document Type: Article

References (46)

1. Parkin DM, Bray FI and Devesa SS: Cancer burden in the year 2000. The global picture. Eur J Cancer 37 (Suppl 8): S4-S66, 2001.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
3. Hidalgo M: Pancreatic cancer. N Engl J Med 362: 1605-1617, 2010.
4. Reisman DN, Strobeck MW, Betz BL, et al: Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression. Oncogene 21: 1196-1207, 2002.
5. Wade PA: Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. Hum Mol Genet 10: 693-698, 2001.
6. Neely KE and Workman JL: The complexity of chromatin remodeling and its links to cancer. Biochim Biophys Acta 1603: 19-29, 2002.
7. Klochendler-Yeivin A, Muchardt C and Yaniv M: SWI/SNF chromatin remodeling and cancer. Curr Opin Genet Dev 12: 73-79, 2002.
8. Davis PK and Brackmann RK: Chromatin remodeling and cancer. Cancer Biol Ther 2: 22-29, 2003.
9. Narlikar GJ, Fan HY and Kingston RE: Cooperation between complexes that regulate chromatin structure and transcription. Cell 108: 475-487, 2002.
10. Langst G and Becker PB: Nucleosome mobilization and positioning by ISWI-containing chromatin-remodeling factors. J Cell Sci 114: 2561-2568, 2001.
11. Kingston RE and Narlikar GJ: ATP-dependent remodeling and acetylation as regulators of chromatin fluidity. Genes Dev 13: 2339-2352, 1999.
12. Burns LG and Peterson CL: The yeast SWI-SNF complex facilitates binding of a transcriptional activator to nucleosomal sites in vivo. Mol Cell Biol 17: 4811-4819, 1997.
13. Wu C: Chromatin remodeling and the control of gene expression. J Biol Chem 272: 28171-28174, 1997.
14. Breeden L and Nasmyth K: Cell cycle control of the yeast HO gene: cis- and trans-acting regulators. Cell 48: 389-397, 1987.
15. Recht J and Osley MA: Mutations in both the structured domain and N-terminus of histone H2B bypass the requirement for Swi-Snf in yeast. EMBO J 18: 229-240, 1999.
16. Phelan ML, Sif S, Narlikar GJ and Kingston RE: Reconstitution of a core chromatin remodeling complex from SWI/SNF subunits. Mol Cell 3: 247-253, 1999.
17. Tyler JK and Kadonaga JT: The 'dark side' of chromatin remodeling: repressive effects on transcription. Cell 99: 443-446, 1999.
18. Wang W, Cote J, Xue Y, et al: Purification and biochemical heterogeneity of the mammalian SWI-SNF complex. EMBO J 15: 5370-5382, 1996.
19. Decristofaro MF, Betz BL, Rorie CJ, Reisman DN, Wang W and Weissman BE: Characterization of SWI/SNF protein expression in human breast cancer cell lines and other malignancies. J Cell Physiol 186: 136-145, 2001.
20. McCarty KS Jr, Miller LS, Cox EB, Konrath J and McCarty KS Sr: Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 109: 716-721, 1985.
21. Bourgo RJ, Siddiqui H, Fox S, et al: SWI/SNF deficiency results in aberrant chromatin organization, mitotic failure, and diminished proliferative capacity. Mol Biol Cell 20: 3192-3199, 2009.
22. Reisman D, Glaros S and Thompson EA: The SWI/SNF complex and cancer. Oncogene 28: 1653-1668, 2009.
23. Wiegand KC, Shah SP, Al-Agha OM, et al: ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363: 1532-1543, 2010.
24. Jones S, Wang TL, Shih Ie M, et al: Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330: 228-231, 2010.
25. Varela I, Tarpey P, Raine K, et al: Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469: 539-542, 2011.
26. Weissman B and Knudsen KE: Hijacking the chromatin remodeling machinery: impact of SWI/SNF perturbations in cancer. Cancer Res 69: 8223-8230, 2009.
27. Roberts CW and Orkin SH: The SWI/SNF complex - chromatin and cancer. Nat Rev Cancer 4: 133-142, 2004.
28. Biegel JA, Kalpana G, Knudsen ES, et al: The role of INI1 and the SWI/SNF complex in the development of rhabdoid tumors: meeting summary from the workshop on childhood atypical teratoid/rhabdoid tumors. Cancer Res 62: 323-328, 2002.
29. Heinemann V, Boeck S, Hinke A, Labianca R and Louvet C: Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 8: 82, 2008.
30. El-Rayes BF and Philip PA: A review of systemic therapy for advanced pancreatic cancer. Clin Adv Hematol Oncol 1: 430-434, 2003.
31. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966, 2007.
32. Glaros S, Cirrincione GM, Muchardt C, Kleer CG, Michael CW and Reisman D: The reversible epigenetic silencing of BRM: implications for clinical targeted therapy. Oncogene 26: 7058-7066, 2007.
33. Reisman DN, Sciarrotta J, Wang W, Funkhouser WK and Weissman BE: Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. Cancer Res 63: 560-566, 2003.
34. Fukuoka J, Fujii T, Shih JH, et al: Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer. Clin Cancer Res 10: 4314-4324, 2004.
35. Batsche E, Yaniv M and Muchardt C: The human SWI/SNF subunit Brm is a regulator of alternative splicing. Nat Struct Mol Biol 13: 22-29, 2006.
36. Martin TA, Harrison G, Mansel RE and Jiang WG: The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol 46: 165-186, 2003.
37. Xue Y, Canman JC, Lee CS, et al: The human SWI/SNF-B chromatin-remodeling complex is related to yeast rsc and localizes at kinetochores of mitotic chromosomes. Proc Natl Acad Sci USA 97: 13015-13020, 2000.
38. Maitra A, Wistuba, II, Washington C, et al: High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss. Am J Pathol 159: 119-130, 2001.
39. Zabarovsky ER, Lerman MI and Minna JD: Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene 21: 6915-6935, 2002.
40. Xia W, Nagase S, Montia AG, et al: BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer. Cancer Res 68: 1667-1674, 2008.
41. Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816, 1993.
42. Duns G, Hofstra RM, Sietzema JG, et al: Targeted exome sequencing in clear cell renal cell carcinoma tumors suggests aberrant chromatin regulation as a crucial step in ccRCC development. Hum Mutat 33: 1059-1062, 2012.
43. Nie Z, Xue Y, Yang D, et al: A specificity and targeting subunit of a human SWI/SNF family-related chromatin-remodeling complex. Mol Cell Biol 20: 8879-8888, 2000.
44. Sekine I, Sato M, Sunaga N, et al: The 3p21 candidate tumor suppressor gene BAF180 is normally expressed in human lung cancer. Oncogene 24: 2735-2738, 2005.
45. Wang X, Nagl NG Jr, Flowers S, Zweitzig D, Dallas PB and Moran E: Expression of p270 (ARID1A), a component of human SWI/SNF complexes, in human tumors. Int J Cancer 112: 636, 2004.
46. Nagl NG Jr, Zweitzig DR, Thimmapaya B, Beck GR Jr and Moran E: The c-myc gene is a direct target of mammalian SWI/SNF-related complexes during differentiation-associated cell cycle arrest. Cancer Res 66: 1289-1293, 2006.